About Us

Back to About Us

Tara Sander Lee, Ph.D.

Associate Scholar

Dr. Sander Lee is an Associate Professor of Pathology at the Medical College of Wisconsin and Scientific Director of Molecular Diagnostics at Children’s Hospital of Wisconsin. She obtained her Ph.D. in biochemistry from the Medical College of Wisconsin, followed by research fellowship training in cell and molecular biology at Harvard Medical School and Boston Children’s Hospital.

Dr. Sander Lee’s career has focused on the pathologic basis of disease in children.  She directs a molecular diagnostics lab that performs genetic testing for the diagnosis and treatment of pediatric disorders such as cystic fibrosis, epilepsy, hearing loss, DiGeorge Syndrome, and hypercoagulation. Her research interests include pharmacogenetics and the development of novel diagnostic tests for the pediatric population. Dr. Sander Lee actively participates in legislative efforts that protect the preborn and promote ethical advances in healthcare.

Latest Research & News

  • Q&A with the Scholars: Science, Ethics, and Fetal Tissue | April 12, 2017

    Tara Sander Lee, Ph.D., is a Molecular and Cell Biologist with over 15 years of experience in academic research and healthcare. In this interview, she discusses genetic testing for diagnosis and treatment of children and the ethical and scientific issues surrounding the use of fetal tissue procured from abortion for research.

  • Written Testimony of Tara Sander Lee, Ph.D., in Support of Texas Bill to Prohibit Human Fetal Tissue Research | February 16, 2017

    On Wednesday, February 15, 2017, the Texas Committee of Health and Human Services held a hearing regarding Texas Senate Bill 8 (SB 8). SB 8 prohibits partial-birth abortions, prohibits donation of human fetal tissue except by certain authorized facilities to accredited universities, and prohibits the purchase or sale of human fetal tissue. Charlotte Lozier Institute Associate Scholar Tara Sander Lee, Ph.D., submitted the following written testimony in support of SB 8.